Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis
| Autor: | Ani Antaramian, Mazen Noureddin, Atef Al Attar |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Liver Cirrhosis
Galectins Inflammation Disease Severity of Illness Index 030226 pharmacology & pharmacy 03 medical and health sciences 0302 clinical medicine Non-alcoholic Fatty Liver Disease Fibrosis Severity of illness medicine Animals Humans Pharmacology (medical) General Pharmacology Toxicology and Pharmaceutics Galectin business.industry Binding protein Blood Proteins General Medicine medicine.disease Blood proteins Disease Models Animal Galectin-3 030220 oncology & carcinogenesis Disease Progression Cancer research Pectins medicine.symptom business |
| Zdroj: | Expert Review of Clinical Pharmacology. 14:457-464 |
| ISSN: | 1751-2441 1751-2433 |
| DOI: | 10.1080/17512433.2021.1894127 |
| Popis: | Galectin-3 (Gal-3) is a β-galactoside binding protein associated with many disease pathologies, including chronic inflammation and fibrogenesis. It has been implicated in the disease severity of NASH, although its precise role is unknown. Inhibition of Gal-3 has shown to improve and prevent fibrosis progression and has now reached phase III clinical trial in NASH patients.This discusses the role of Gal-3 in NASH. It brings together the current findings of Gal-3 in NASH and hepatic fibrosis by analyzing recent data from animal model studies and clinical trials.Gal-3 inhibitors, in particular, Belapectin (GR-MD-02), have shown promising results for NASH with advanced fibrosis. In a phase 2 trial, Belapectin did not meet the primary endpoint. However, a sub-analysis of Belapectin among a separate group of patients without esophageal varices showed 2 mg/kg of GR-MD-02 reduced HVPG and the development of new varices. A subsequent study is under way, aiming to replicate the positive findings in phase 2 and demonstrate greater efficacy. If Belapectin is shown to be effective, it will be coupled with other drugs that target steatohepatitis to maximize efficacy and disease reversal. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|